To this end, we evaluated the association between Ripk1, Ripk3, and Mlkl mRNA levels and the levels of soluble Aβo in postmortem brain samples of AD patients at different stages of the disease (clinical data of the subjects used in this study are summarized in Table 2). The gene discussed is MLKL; the disease is Alzheimer disease.